【摘要】

【摘要】目的 探讨阿托伐他汀联合多奈哌齐对阿尔茨海默病患者精神行为、痴呆程度改善效果及安全性。
方法 抽取2018年7月至2020年3月某院收治的182例阿尔茨海默病患者为研究对象，采用随机数字表法分为对照组和研究组，每组91例。对照组在常规治疗基础上给予多奈哌齐治疗，研究者在对照组基础上加用阿托伐他汀片治疗，治疗周期6个月。采用日常生活能力量表（ADL）、简易精神认知量表（MMSE）、Blessed痴呆量表（BDS）评价治疗前后患者生活质量及认知能够改善情况，比较治疗前后两组患者血清学指标变化情况，采用药物副反应量表（TESS）评价联合用药安全性。
结果 治疗前，两组患者ADL、MMSE、BDS评分及TC、TG、HDL、LDL等血清指标采用均为统计学意义（P＞0.05），治疗后，研究组ADL、MMSE、BDS评分及TC、TG、HDL、LDL等血清指标改善均明显优于对照组，差异有统计学意义（P＜0.05）。两组TESS各项评分差异无统计学意义（P＞0.05）。
结论 阿托伐他汀与多奈哌齐联合用药可有效改善阿尔茨海默病患者精神行为、痴呆程度、认知能力及血清学指标，提升其日常生活能力，且不增加药物毒副反应，临床疗效及安全性均佳。

【Abstract】

【Abstract】 Objective To explore the effect and safety of atorvastatin combined with donepezil on mental behavior and dementia in patients with Alzheimer's disease.
Methods A sample of 182 patients with Alzheimer's disease admitted to a hospital from July 2018 to March 2020 were selected as the research objects, and they were divided into a control group and a study group using a random number table method, with 91 cases in each group.The control group was treated with donepezil on the basis of conventional treatment, and the investigator was treated with atorvastatin tablets on the basis of the control group. The treatment period was 6 months. The ability of daily living scale (ADL), the simple mental cognition scale (MMSE), and the Blessed dementia scale (BDS) were used to evaluate the patient’s quality of life and cognition improvement before and after treatment, and to compare the changes in serum indexes of the two groups before and after treatment According to the situation, the Drug Adverse Reaction Scale (TESS) was used to evaluate the safety of combination medication.
Results Before treatment, the two groups of patients’ ADL, MMSE, BDS scores and TC, TG, HDL, LDL and other serum indexes were all statistically significant (P>0.05). After treatment, the study group’s ADL, MMSE, BDS scores and TC, TG The improvement of serum indexes such as, HDL, LDL were significantly better than the control group, the difference was statistically significant (P<0.05). There was no significant difference in TESS scores between the two groups (P>0.05).
Conclusion   The combination of atorvastatin and donepezil can effectively improve the mental behavior, degree of dementia, cognitive ability and serological indicators of patients with Alzheimer's disease, and improve their ability of daily living without increasing drug toxicity. The clinical efficacy and safety All good.